Self-reported adverse events within the seven days following the Spikevax® (Moderna) vaccination.

Objective: Continuous monitoring of COVID-19 vaccines safety may provide  additional information to health care professionals and the general population.  The aim of the present study was to analyze the local and systemic adverse  events following the administration of the Spikevax® (Moderna) vaccine, and  to identify the factors related to greater reactogenicity.

Method: Using a telephone survey, we interviewed 331 recipient of the  Spikevax® vaccine (50.

Reactogenicity of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19 in workers of a tertiary hospital.

Objective: To analyze the local and systemic reactions that appeared after the first and second dose of the BNT162b2 vaccine against COVID‑19 (Pfizer- BioNTech) in a sample of workers from a tertiary hospital, and to identify the  factors related to greater vaccine reactogenicity.

Method: A self-administered questionnaire was used to interview 291 workers  from a tertiary hospital who received the BNT162b2 vaccine against COVID-19  between January and March 2021. The questionnaire included questions about  the sociodemographic variables of the participants, previous COVID-19  infection, and local and systemic reactions after the first and second dose of  the vaccine.